Preclinical Performance Evaluation of Percutaneous Glucose Biosensors

Soto, Robert J.

doi:10.1177/1932296815590628

Cited by 6 publications

(11 citation statements)

References 44 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 30 d NO-releasing sensors proved fully compliant with the <15% MARD benchmark for at least 21 d and just exceed the ISO standard after 28 d of implantation (18.1%). Reporting MARD over time has been uncommon practice for prior NO-releasing glucose sensor studies, but it is vital to understand the impact of NO on sensor performance . The in vivo sensitivity for NO-releasing biosensors was retained at a slightly higher level than controls at extended implant periods (Figure s-4).…”

Section: Resultsmentioning

confidence: 99%

“…Representative raw and calibrated glucose traces are provided in the Supporting Information (Figure S-2). Of note, the emerging prevalence of predictive calibration (i.e., flash glucose monitoring) may indicate that future studies will neither require such frequent recalibration, nor employ calibration points from inside the data set being calibrated. − …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Accurate Continuous Glucose Biosensors via Extended Nitric Oxide Release

et al. 2019

Self Cite

View full text Add to dashboard Cite

Analytical performance and tissue interactions of nitric oxide (NO)-releasing continuous glucose sensors were evaluated over a 28 d study in a diabetic swine model. Interstitial glucose was detected using an implanted needletype amperometric glucose sensor. Two NO-release durations from the sensor surface were achieved by doping the membranes with nonporous (14 d release) or porous (30 d release) S-nitrosothiol-functionalized silica nanoparticles. Numerical and clinical accuracy of the sensors were assessed at time points (1, 7, 14, 21, and 28 d) following implantation. Nitric oxide-releasing sensors demonstrated accurate glucose detection over a time period directly correlated with the active release of NO. Silica particle-doped sensors that released NO for 30 d showed standard-compliant accuracy (i.e., mean absolute relative difference ≤ 15%) for >3 weeks post-implantation. Histological staining for inflammatory biomarkers suggested that the observed performance improvement was the result of decreased inflammatory cell count and a lower density collagen capsule.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Long-Term Accurate Continuous Glucose Biosensors via Extended Nitric Oxide Release

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The chief problem to their use is the foreign body response that impairs sensor performance. 154 It may be that the finding that very small electrodes remain functional will be very useful to other health related fields involving biosensors.…”

Section: Discussionmentioning

confidence: 99%

Hitchhiker’s Guide to Voltammetry: Acute and Chronic Electrodes for in Vivo Fast-Scan Cyclic Voltammetry

Rodeberg

Sandberg

Johnson

et al. 2017

ACS Chem. Neurosci.

192

216

View full text Add to dashboard Cite

Fast-scan cyclic voltammetry (FSCV) has been used for over 20 years to study rapid neurotransmission in awake and behaving animals. These experiments were first carried out with carbon-fiber microelectrodes (CFMs) encased in borosilicate glass, which can be inserted into the brain through micromanipulators and guide cannulas. More recently, chronically implantable CFMs constructed with small diameter fused-silica have been introduced. These electrodes can be affixed in the brain with minimal tissue response, which permits longitudinal measurements of neurotransmission in single recording locations during behavior. Both electrode designs have been used to make novel discoveries in the fields of neurobiology, behavioral neuroscience, and psychopharmacology. The purpose of this Review is to address important considerations for the use of FSCV to study neurotransmitters in awake and behaving animals, with a focus on measurements of striatal dopamine. Common issues concerning experimental design, data collection, and calibration are addressed. When necessary, differences between the two methodologies (acute vs chronic recordings) are discussed. The topics raised in this Review are particularly important as the field moves beyond dopamine toward new neurochemicals and brain regions.

show abstract

“…The FBR causes inflammation and leads to walling off the device by an avascular fibrous capsule. Examples of devices that suffer from the FBR include continuous glucose monitoring systems, whose signals degrade as a result of the fibrous capsule, causing the sensor to fail . Tissue engineering is also adversely affected by the FBR where inflammation impedes tissue growth and fibrous encapsulation delays or even prevents integration. − The hallmarks of the FBR have been well documented to a wide range of implanted materials, , but approaches to combat the FBR remain elusive.…”

Section: Introductionmentioning

confidence: 99%

Prostaglandin E2 and Its Receptor EP2 Modulate Macrophage Activation and Fusion in Vitro

Saleh

Vanderheyden

Frederickson

et al. 2020

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

The foreign body response (FBR) has impaired progress of new implantable medical devices through its hallmark of chronic inflammation and foreign body giant cell (FBGC) formation leading to fibrous encapsulation. Macrophages are known to drive the FBR, but efforts to control macrophage polarization remain challenging. The goal for this study was to investigate whether prostaglandin E2 (PGE2), and specifically its receptors EP2 and/or EP4, attenuate classically activated (i.e., inflammatory) macrophages and macrophage fusion into FBGCs in vitro. Lipopolysaccharide (LPS)-stimulated macrophages exhibited a dose-dependent decrease in gene expression and protein production of tumor necrosis factor alpha (TNF-α) when treated with PGE2. This attenuation was primarily by the EP4 receptor, as the addition of the EP2 antagonist PF 04418948 to PGE2-treated LPS-stimulated cells did not recover TNF-α production while the EP4 antagonist ONO AE3 208 did. However, direct stimulation of EP2 with the agonist butaprost to LPS-stimulated macrophages resulted in a ∼60% decrease in TNF-α secretion after 4 h and corresponded with an increase in gene expression for Cebpb and Il10, suggesting a polarization shift toward alternative activation through EP2 alone. Further, fusion of macrophages into FBGCs induced by interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF) was inhibited by PGE2 via EP2 signaling and by an EP2 agonist, but not an EP4 agonist. The attenuation by PGE2 was confirmed to be primarily by the EP2 receptor. Mrc1, Dcstamp, and Retlna expressions increased upon IL-4/GM-CSF stimulation, but only Retnla expression with the EP2 agonist returned to levels that were not different from controls. This study identified that PGE2 attenuates classically activated macrophages and macrophage fusion through distinct EP receptors, while targeting EP2 is able to attenuate both. In summary, this study identified EP2 as a potential therapeutic target for reducing the FBR to biomaterials.

show abstract

Preclinical Performance Evaluation of Percutaneous Glucose Biosensors

Cited by 6 publications

References 44 publications

Long-Term Accurate Continuous Glucose Biosensors via Extended Nitric Oxide Release

Long-Term Accurate Continuous Glucose Biosensors via Extended Nitric Oxide Release

Hitchhiker’s Guide to Voltammetry: Acute and Chronic Electrodes for in Vivo Fast-Scan Cyclic Voltammetry

Prostaglandin E2 and Its Receptor EP2 Modulate Macrophage Activation and Fusion in Vitro

Contact Info

Product

Resources

About